ClinicalTrials.gg
AvailableNCT07159464Updated Oct 9, 2026

Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Completed the CSL312_3003 Study

An expanded access record providing CSL312 in Hereditary Angioedema (HAE), sponsored by CSL Behring. Available. Open to participants aged Up to 11 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by CSL Behring (part of CSL Limited) · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Individual patients
Ages
Up to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Angioedemas, Hereditary by CSL Limited — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · CSL Limited.

Other kind
Only one
of the 11
Registered
11th of 11
by date

Among the 11 studies in Angioedemas, Hereditary by CSL Limited, this one is the only one of another kind, and was the 11th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 11 studies in Angioedemas, Hereditary by CSL Limited is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: Up to 11 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Angioedemas, Hereditary by CSL Limited, or all of them as a file.
02

Study summary

This protocol for post study access allows pediatric participants (2-11 years old at the time of consent) with HAE who have completed study CSL312_3003 (NCT05819775) to continue treatment with CSL312 for routine prevention of HAE attacks. The continuing treatment with the study product will be administered under a Post Study Access program in accordance with the applicable laws and regulations, to be dictated by CSL Behring (Sponsor) and approved by the appropriate local/central Ethics Committees and all other competent authorities required by law, as applicable.

03

Conditions studied

  • Hereditary Angioedema (HAE)
04

Who can participate

Ages eligible
Up to 11 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of treatment period in study CSL312_3003 (NCT05819775)
  • The participant responded to CSL312 treatment with no or very limited number of HAE attacks during the CSL312_3003 study
  • The participant experienced no adverse effects associated with CSL312 treatment
  • In the opinion of the treating physician, the participant continues to receive benefit from CSL312
  • There is no other suitable alternative prophylactic treatment available at the time of consenting into the Post Study Access program

Exclusion criteria

Exclusion Criteria:

  • In the opinion of the treating physician, participant may not be compliant with the Protocol requirements
  • Participant is 12 years or older at the time of consent
  • In the opinion of the treating physician, other study medication of prophylaxis treatment of HAE may benefit the participant more than continuing treatment with CSL312
  • Participant who is pregnant, breastfeeding, or not willing to cease breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

  • BiologicalGaradacimabStudies of GaradacimabGaradacimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)

    Also known as: Garadacimab

06

Where to request access

No study locations are listed for this record.

07

Updates

1 registry update since Sep 25, 2026
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

08

Registry details

Key details

Study ID
NCT07159464
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Sep 8, 2025
Last update
Oct 9, 2026

Study contacts

Trial Registration Coordinator
Contact
clinicaltrials@cslbehring.com
1-610-878-4697
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion